July 2020
Volume 61, Issue 9
Open Access
ARVO Imaging in the Eye Conference Abstract  |   July 2020
Evaluating the long-term effects of anti-vascular endothelial growth factor therapy on choroidal neovascularization in age-related macular degeneration using optical coherence tomography angiography
Author Affiliations & Notes
  • Emily Levine
    New England Eye Center , Boston, Massachusetts, United States
    Tufts University School of Medicine, Boston, Massachusetts, United States
  • Eugenia Paula Custo Greig
    New England Eye Center , Boston, Massachusetts, United States
    Yale University School of Medicine, New Haven, Connecticut, United States
  • Luisa Mendonca
    New England Eye Center , Boston, Massachusetts, United States
  • Shilpa Gulati
    New England Eye Center , Boston, Massachusetts, United States
  • Ivana Despotovic
    New England Eye Center , Boston, Massachusetts, United States
  • Eric Moult
    Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
  • James Fujimoto
    Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
  • Adil El-Maftouhi
    Centre Ophtalmologique Rabelais, France
  • Maddalena Quaranta-el Maftouhi
    Centre Ophtalmologique Rabelais, France
  • Nora Muakkassa
    Denver Eye Surgeons, Colorado, United States
    New England Eye Center , Boston, Massachusetts, United States
  • Caroline Baumal
    New England Eye Center , Boston, Massachusetts, United States
  • Andre Witkin
    New England Eye Center , Boston, Massachusetts, United States
  • Jay Duker
    New England Eye Center , Boston, Massachusetts, United States
  • Nadia Waheed
    New England Eye Center , Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Emily Levine, None; Eugenia Custo Greig, None; Luisa Mendonca, None; Shilpa Gulati, None; Ivana Despotovic, None; Eric Moult, None; James Fujimoto, Carl Zeiss Meditec (F), Carl Zeiss Meditec (C), Optovue (C), Optovue (R), Optovue (S), Topcon (F), Topcon (C); Adil El-Maftouhi, Bayer (F), Bayer (I), EBC (F), EBC (I), Optovue (F), Optovue (I); Maddalena Quaranta-el Maftouhi, Bayer (C), Novartis (C); Nora Muakkassa, None; Caroline Baumal, Allergen (R), Carl Zeiss Meditec (R), Genentech (R), Optovue (R); Andre Witkin, None; Jay Duker, Aldeyra (C), Allergan (C), Aura Biosciences (C), Bausch Health (C), Beyeonics (C), Carl Zeiss Meditec (F), Eleven Oncology (S), Eye-Point Pharma (S), Hemera Biosciences (I), Merck (C), Novartis (C), Optovue (F), Roche (C); Nadia Waheed, Apellis (C), Astellas (C), Boehringer Ingelheim (C), Boston Image Reading Center (I), Gyroscope (I), Gyroscope (S), Nidek (R), Novartis (C), Ocudyne (I), Regeneron (C), Roche/Genentech (C), Topcon (C)
  • Footnotes
    Support  Massachusetts Lions Club grant, Research to Prevent Blindness Challenge grant
Investigative Ophthalmology & Visual Science July 2020, Vol.61, PB0025. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emily Levine, Eugenia Paula Custo Greig, Luisa Mendonca, Shilpa Gulati, Ivana Despotovic, Eric Moult, James Fujimoto, Adil El-Maftouhi, Maddalena Quaranta-el Maftouhi, Nora Muakkassa, Caroline Baumal, Andre Witkin, Jay Duker, Nadia Waheed; Evaluating the long-term effects of anti-vascular endothelial growth factor therapy on choroidal neovascularization in age-related macular degeneration using optical coherence tomography angiography. Invest. Ophthalmol. Vis. Sci. 2020;61(9):PB0025.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Optical coherence tomography angiography (OCTA) allows for precise, non-invasive monitoring of changes to choroidal neovascularization (CNV) structure over time. The short-term effects of anti-vascular endothelial growth factor (anti-VEGF) treatment on CNV morphology is well described, but long-term studies on morphologic changes and correlation of such to the type of CNV have not been conducted. This study aims to determine if different types of CNVs in neovascular AMD (nAMD) behave differently with anti-VEGF treatment as visualized on OCTA.

Methods : AMD Patients with treatment naive type 1, type 2, and type 3 CNVs were retrospectively screened for baseline and follow-up OCTA imaging 10 or more months after initial treatment. Images were graded for CNV type, area, activity, mature versus immature vessels, vessel density, presence of atrophy, atrophy location and area. Growth rate was calculated as the percent change in lesion area from baseline over the years of follow-up. The occurrence of complete regression and the percent of lesions that grew, remained stable, and shrunk per type was also evaluated. Statistical analysis assessed the differences in features across types and the correlation of these variables with growth rate and the number of injections.

Results : Forty-five eyes from 43 patients with a mean follow-up of 2 years (± 1 year) were evaluated. Twenty-seven lesions were classified as pure type 1 CNVs, 13 CNVs had a type 2 component, and 5 CNVs had a type 3 component. Of these cases, two mixed-type CNVs were considered to have completely regressed. Most type 1 and all type 3 CNVs (43% and 100%, respectively) shrunk while most type 2 CNVs (45%) grew in the follow-up. There was no difference in the magnitude of growth rate across type. The growth rate of type 3 CNVs was inversely correlated with the number of injections (p < 0.001, ρ =1).

Conclusions : Complete regression of a CNV network exposed to anti-VEGF in nAMD is rare. Analysis of this data found no difference in the magnitude of growth rate across type, and no significant effect from varying anti-VEGF exposure in type 1 and type 2 lesions. This work highlights the differences between type 1 and 2 CNVs versus type 3 lesions and emphasizes the role of anti-VEGF as anti-leakage rather than vascular regression agents in nAMD.

This is a 2020 Imaging in the Eye Conference abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×